FDA Approves Novel Treatment for Hairy Cell Leukemia

Lumoxiti, a CD22 - directed cytotoxin, approved for adults who have had at least two prior therapies
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news